Quarterly report pursuant to Section 13 or 15(d)

Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail)

v3.22.2.2
Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Outstanding and nonvested, Beginning Balance, Number of Shares [1]     3,400    
Granted, Number of Shares [2]     2,075    
Vested, Number of Shares     (800)    
Forfeited, Number of Shares [3]     (318)    
Outstanding and nonvested, Ending Balance, Number of Shares [1] 4,357   4,357   3,400
Number of Shares, Expected to vest [4] 3,463   3,463    
Outstanding and nonvested, Beginning Balance, Weighted Average Grant Date Fair Value Per Share [1]     $ 45.26    
Granted, Weighted Average Grant Date Fair Value Per Share [2]     36.06    
Vested, Weighted Average Grant Date Fair Value Per Share     48.69    
Forfeited, Weighted Average Grant Date Fair Value Per Share [3]     42.82    
Outstanding and nonvested, Ending Balance, Weighted Average Grant Date Fair Value Per Share [1] $ 40.43   40.43   $ 45.26
Expected to vest, Ending Balance, Weighted Average Grant Date Fair Value Per Share [4] $ 40.15   $ 40.15    
SARs [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of Awards Outstanding, Beginning Balance [5]     2,622    
Granted, Number of Awards 0 0 0 0  
Exercised, Number of Awards     (55)    
Forfeited, Number of Awards     (226)    
Number of Awards Outstanding, Ending Balance [5] 2,341   2,341   2,622
Number of Awards Exercisable, Ending Balance [5] 2,341   2,341    
Number of Awards Vested and expected to vest, Ending Balance 2,341   2,341    
Weighted Average Exercise Price Per Award Outstanding, Beginning Balance [5]     $ 27.10    
Granted, Weighted Average Exercise Price Per Award     0    
Exercised, Weighted Average Exercise Price Per Award     23.18    
Forfeited, Weighted Average Exercise Price Per Award     24.70    
Weighted Average Exercise Price Per Award Outstanding, Ending Balance [5] $ 27.42   27.42   $ 27.10
Exercisable, Weighted Average Exercise Price Per Award, Ending Balance [5] 27.42   27.42    
Weighted Average Exercise Price Per Award, Vested and expected to vest, Ending Balance $ 27.42   $ 27.42    
Weighted Average Remaining Contractual Term Outstanding [5]     3 years 2 months 12 days   3 years 9 months 18 days
Exercisable Weighted Average Remaining Contractual Term [5]     3 years 2 months 12 days    
Weighted Average Remaining Contractual Term, Vested and expected to vest     3 years 2 months 12 days    
Aggregate Intrinsic Value Outstanding [5],[6] $ 2.2   $ 2.2   $ 36.3
Exercisable, Aggregate Intrinsic Value [5],[6] 2.2   2.2    
Aggregate Intrinsic Value, Vested and expected to vest [6] $ 2.2   $ 2.2    
[1] Includes 1,387,708 and 913,388 performance-based restricted stock units as of September 30, 2022 and December 31, 2021, respectively, which represents the maximum amount that can vest.
[2] Includes 559,430 performance-based restricted stock units.
[3] Includes 94,110 performance-based restricted stock units
[4] Includes 564,871 performance-based restricted stock units.
[5] Includes 0.8 million performance condition SARs
[6] The intrinsic value is the amount by which the current market value of the underlying stock exceeds the exercise price of the SARs.